Cipla gets USFDA approval for HIV drug

Pharmaceutical firm Cipla has got tentative approval from the USFDA for its abbreviated new drug application (ANDA) for anti-HIV/AIDS drug Slamivudine.

By PTI | Jun 26, 2006, 12.00 PM IST

NEW DELHI: Pharmaceutical firm Cipla has got tentative approval from the USFDA for its abbreviated new drug application (ANDA) for anti-HIV/AIDS drug Slamivudine.

According to information available on the USFDA website, the tentative approval is for the oral solution of strength 10mg per ml.

The drug is in a class of medications called nucleoside reverse transcriptase inhibitors. It works by stopping the spread of the HIV and hepatitis B viruses.

Start a SIP with as low as ₹500 with ET Money App!